EMA’s CHMP recommends approval of Bristol Myers Squibb’s HCC treatment combo

The CHMP decision is based on outcomes from the Phase III CheckMate -9DW trial. Credit: National Cancer Institute on Unsplash.



  • EMA’s CHMP recommends approval of Bristol Myers Squibb’s HCC treatment combo